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Abstract  20 
Endometriosis is an incurable gynecological disorder characterized by debilitating pain and the 21 
establishment of innervated endometriosis lesions outside the uterus. In a preclinical mouse model of 22 
endometriosis we demonstrated overexpression of the PGE2-signaling pathway (including COX-2, EP2, 23 
EP4) in endometriosis lesions, dorsal root ganglia (DRG), spinal cord, thalamus and forebrain. TRPV1, 24 
a PGE2-regulated channel in nociceptive neurons was also increased in the DRG. These findings support 25 
the concept that an amplification process occurs along the pain neuroaxis in endometriosis.  We then 26 
tested TRPV1, EP2, and EP4 receptor antagonists: EP2 antagonist was the most efficient analgesic, 27 
reducing primary hyperalgesia by 80% and secondary hyperalgesia by 40%. In this study we 28 
demonstrate reversible peripheral and central hyperalgesia in mice with induced endometriosis.  29 
  30 
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Endometriosis is a chronic gynecological disorder affecting 176 million women worldwide1 31 
associated with chronic pain and infertility. Current therapies include invasive surgery, drugs that 32 
suppress endogenous hormones2 and non-steroidal anti-inflammatory drugs (NSAIDs) all of which have 33 
unwanted side effects. Better treatments for endometriosis-associated pain are needed but their 34 
development has been hampered by the lack of a robust preclinical model that fully reproduces the 35 
altered pain perception experienced by women with endometriosis.  36 
Endometriosis is caused by the presence of endometrial-like tissue (endometriosis lesions) outside 37 
of the uterine cavity3. An association between small nerve fiber infiltration of endometriosis lesions and 38 
increased central and peripheral pain has been described (reviewed in4). Alterations in pain perception 39 
in women are thought to involve release of inflammatory mediators and neuropeptides by efferent 40 
peripheral nerve endings,5 an increase in the sensitivity of nociceptive neurons,6 and peripheral 41 
hyperalgesia. Continuous input from peripheral afferents can also trigger spinal hyper-excitability 42 
(central sensitization)7 resulting in increased pain perception, secondary hyperalgesia and allodynia8. 43 
Prostaglandin E2 (PGE2) is a well-established mediator of inflammation and nociception in 44 
inflammatory9, 10 and neuropathic pain conditions11 and synthesis of prostaglandins within endometriosis 45 
lesions has previously been reported 12, 13, 14, 15. As the association of PGE2 signaling and endometriosis 46 
is well established we chose to validate this pathway as a target for pain attenuation in our mouse model. 47 
 A rat model of endometriosis exhibits vaginal hyperalgesia and increased abdominal muscle 48 
activity16, 17, 18. Recently, a study utilizing the same rat model demonstrated increased hyperalgesia in 49 
response to von Frey filaments, although an increase was also observed in the sham group19. Another 50 
model using autologous transplantation of endometrial tissue onto the gastrocnemius muscle20 has 51 
proved useful for the identification of pronociceptive molecules that may be relevant in endometriosis21. 52 
Our murine model of endometriosis uses decidualized endometrial tissue injected (rather than sutured) 53 
into the peritoneum of recipient mice22. Resultant lesions phenocopy those in women; they are 54 
vascularized, innervated, infiltrated by macrophages and also exhibit oestrogen-dependent regulation of 55 
vascular-nerve and macrophage-nerve interactions23, 24. The aim of our study was to determine if mice 56 
with induced endometriosis exhibit peripheral (abdominal) and central (secondary/referred) 57 
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hyperalgesia and to test compounds targeting prostaglandin receptors to validate this model as a platform 58 
for preclinical testing of compounds to treat pain.  59 
Results 60 
Induction of endometriosis lesions resulted in altered pain-associated behaviors We confirmed 61 
lesions in 90% of endometriosis mice (Endo) and those that we did not recover lesions from were 62 
excluded from our analysis. The average number of lesions recovered was 1.9 (Supplementary Table 63 
1). Endo mice had significantly higher levels of abdominally-directed licking (Fig.1a) and decreased 64 
exploratory activity (Fig.1b) compared to controls (p<0.001). Endo mice had significantly lower 65 
mechanical withdrawal thresholds for von Frey filaments, not only on the abdomen (Fig.1c) but also on 66 
the hind-paws (Fig.1d; p<0.05 and p<0.01, respectively). We found no correlation between mechanical 67 
allodynia (hypersensitivity) and number of lesions in mice with endometriosis (Supplementary Fig.1a-68 
b) 69 
Over-representation of the PGE2 signaling pathway and nociceptive ion channels in endometriosis 70 
lesions and in the nervous system of mice with endometriosis  71 
Consistent with our previous studies22, 23, 24 endometriosis-like lesions were recovered from the walls 72 
of the parietal peritoneum and the visceral peritoneum covering the uterus, gut, and intestines; 73 
mesentery associated with the gut and intestines; adipose associated with the kidney; and underneath 74 
the kidneys. EP2, EP4, cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) were significantly 75 
increased in endometriosis lesions compared to the peritoneum of naive mice (NP) or mice with 76 
endometriosis (EP; p<0.01;Supplementary Fig.2a-d); EP2, EP4, COX-1 and COX-2 proteins were 77 
immunolocalised to glandular and stromal cells in lesions and mesothelial cells in the peritoneum 78 
(Supplementary Fig 2). PGE2 concentrations in the peritoneal fluid of Endo mice were significantly 79 
increased (p<0.05; Supplementary Fig.2E). mRNA concentrations of EP1 and EP3 were unchanged 80 
(Supplementary Fig.2f-g). EP2, Cox-1, Scn11a and Trpv1 mRNA concentrations were significantly 81 
increased in dorsal root ganglia (DRG; clusters of cell bodies of afferent sensory neurons that transmit 82 
noxious stimuli from the periphery to the spinal cord) from endometriosis mice (p<0.05; Fig.2a-d); 83 
EP4 and Cox-2 were unchanged (Supplementary Fig.3c-d). Trpv1 mRNA was also increased in the 84 
DRGs from OVX+E2 mice. Dual immunofluorescence showed that in small DRG cells  expressing 85 
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peripherin (a marker for small unmyelinated sensory neurons; C-fibre nociceptors), the proportion that 86 
were immunopositive for TRPV1 was significantly increased in Endo mice compared to naïve and 87 
OVX+E2-treated controls (p<0.05; Fig.2e, f). The proportion of TRPV1-immunopositive neurons in 88 
DRG that express EP2 was also increased in these animals (Supplementary Fig.3e-f). Mice with 89 
endometriosis had significantly increased concentrations of COX-2 protein in the spinal dorsal horn 90 
(p<0.001), the thalamus (p<0.001) and the anterior cingulate cortex of the brain (p<0.001; Fig.2f, i). 91 
All of these changes would be expected to contribute to pain hypersensitivity. 92 
Pre-clinical testing and stratification of potential therapies identified EP2 as a key target  93 
Figure 3 indicates that injection of the TRPV1 inhibitor JNJ 17203212 (Fig3a, b) or the EP4 antagonist 94 
L-161982 (Fig.3c, d), did not reverse abdominal or paw hyperalgesia to a statistically significant extent. 95 
Administration of the EP2 antagonist TG6-10-1 resulted in a statistically significant reversal of 96 
mechanical allodynia as tested on the abdomen (p<0.05) at 45 mins post administration but this did not 97 
reach significance for the hind paw (Fig.3e, f). Time-course graphs are shown in Supplementary Fig.4. 98 
Results were extended using injection (Fig 3g, h) or oral administration (Fig 4a, b) of a second EP2 99 
antagonist (PF-04418948)25 and this reduced allodynia in both abdomen and hind-paw tests (p<0.001 100 
using either route). Oral administration resulted in striking, time dependent, and significant impacts 101 
(Fig.4a, b, p<0.001).   102 
Discussion 103 
The re-purposing of drugs and the development of novel treatments for endometriosis-104 
associated pelvic pain has been limited by the paucity of accessible pre-clinical models. In this study we 105 
tested pain responses in a mouse model of endometriosis that phenocopies interactions between 106 
endometriosis lesions and host tissue22, 24 identified in human tissues. Endometriosis (Endo) mice 107 
exhibited increased levels of abdominally-directed grooming, a reduction in normal exploratory 108 
behavior and reduced mechanical withdrawal thresholds on both the abdomen and plantar hind-paw. 109 
The rodent models reported by Berkley, and by Levine and Giudice, both report evidence of 110 
hyperalgesia 16, 26, 27 20. These models involve the artificial implantation of uterine tissue (full thickness 111 
i.e. endometrium plus myometrium) onto the mesenteric arteries of the small intestine and the 112 
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gastrocnemius muscle, respectively. Therefore the microenvironment of the endometriosis lesion 113 
created in these models may not closely mirror that of the peripheral lesions in women.  114 
PGE2 is increased in the peritoneal fluid of patients with endometriosis28, this up-regulation 115 
results from induced expression of cyclooxygenase-2 (COX-2) in endometriotic tissue. PGE2 is thought 116 
to be a key player in the pathophysiology of endometriosis and studies have shown that inhibition of 117 
COX-2 decreases survival, migration and invasion of endometriotic cells13. The same authors 118 
demonstrated that inhibition of EP2 and EP4 can inhibit the epithelial and stromal cell invasion via 119 
suppression of matrix metalloproteinases29. Attenuation of PGE2 signaling via lipoxin A4 can also 120 
modulate disease progression by attenuation of pro-inflammatory and angiogenic mediators30. A recent 121 
study using xenografted endometriotic cell lines in a nude mouse model of endometriosis demonstrated 122 
that dual inhibition of EP2 and EP4 could attenuate mechanical hyperlagesia of the pelvic floor via 123 
suppression of pro-inflammatory mediators in dorsal root ganglia31, however the authors did not test 124 
secondary hyperalgesia or analyze changes in the central nervous system.  125 
In our mouse model we confirmed that the prostaglandin E signaling pathway was over-126 
expressed in the pelvic cavity of our Endo mice and concentrations of PGE2 were increased in their 127 
peritoneal fluid. Release of PGE2 at sites of peripheral inflammation can contribute to pain 128 
hypersensitivity by lowering the threshold and enhancing the excitability of nociceptor sensory fibers32. 129 
This occurs at least in part via EP receptor-mediated activation of intracellular kinases in the nociceptor 130 
terminal that causes phosphorylation of the nociceptive ion channel TRPV133, 34 and an up-regulation of 131 
Nav1.9 voltage-gated sodium channel (SCN11A) 35, which is then transported to peripheral nerve 132 
terminals to contribute to increased excitability7. We detected a significant increase in expression of 133 
EP2, COX-1 and both TRPV1 and SCN11A ion channels in the DRGs of mice with endometriosis. This 134 
parallels observations of increased COX-1 and COX-2 in TRPV1-positive DRG cells in other models 135 
of inflammatory hyperalgesia36. TRPV1-immunoreactivity was increased in small, peripherin-positive, 136 
nociceptive neurons in DRG of mice with endometriosis and EP2 expression was further increased in 137 
these cells. All of these findings are consistent with the development of sensory neuron hyperexcitability 138 
in our mice. The possibility of some additional role of prostaglandin signaling in non-neuronal cells, as 139 
seen in some other pain models37 cannot be excluded. Elevated TRPV1 expression in small DRG cells 140 
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innervating pelvic regions in mice with endometriosis is consistent with our previous findings that 141 
TRPV1 mRNA is elevated in peritoneal lesions from women with endometriosis38.  142 
 In this study, assessment of COX-2 expression in CNS regions within the pain-processing 143 
pathway revealed striking increases in expression at spinal, thalamic and cortical levels. COX-2 144 
expression in the CNS is established as a sensitive and responsive biomarker of centralized 145 
inflammatory pain39, 40, 41 and is an important finding consistent with the inflammatory pain and 146 
widespread central sensitization as experienced by women with endometriosis. The phenomenon of 147 
central sensitization42 has been postulated as a key contributor to the co-morbid pain syndromes 148 
experienced by women with the condition4. Central sensitization is described as a maladaptation of the 149 
CNS resulting from continued or repetitive input from nociceptors, in endometriosis it is likely that this 150 
input is provided by afferent nerve fibers innervating endometriosis lesions. One of the first steps in this 151 
process of central sensitization is an increase in expression of genes encoding neurotrophins, 152 
neuropeptides and ion channels critical in sensing and detecting noxious stimuli8. In the model of 153 
endometriosis generated by Berkley et al, rats exhibit vaginal hyperalgesia26 and it is argued by the 154 
authors that this finding suggests central sensitization as an underlying factor because spinal segments 155 
associated with the induced endometriosis cysts are distant from spinal segments receiving input from 156 
the vagina43, 44. Using this same model a decrease in μ-opioid and NMDA receptor immunoreactivity in 157 
the periaqueductal gray area of the brain was detected in rats with endometriosis compared to controls. 158 
Torres-Reverón et al suggested that a decrease in NMDA receptor expression could be an attempt to 159 
homeostatically regulate pain perception, whilst a decrease in μ-opioid receptor expression suggests 160 
decreased modulatory activity of opioid receptors that could contribute to hyperalgesia in the 161 
condition45. We have also documented molecular alterations in the CNS of mice with endometriosis and 162 
we believe this as an important step change in our understanding of endometriosis-associated pain.  163 
 Having demonstrated amplified pain behaviors, we tested therapeutic strategies for reversal of 164 
mechanical allodynia. The effects of TRPV1 inhibition were modest, whilst antagonism of EP2, 165 
particularly following oral administration of the highly selective antagonist PF-04418948 had 166 
pronounced effects on peripheral and secondary hyperalgesia. This is consistent with reports that EP2 167 
null mice do not develop spinal hyperalgesia following induced peripheral inflammation46. In a recent 168 
Preclinical evaluation of pain in endometriosis 
 8 
study, the effect of a mixture of EP2/EP4 antagonists had a modest impact on pelvic floor hyperalgesia 169 
in mice which may either reflect the limited specificity of the antagonists tested or use of human 170 
endometriotic cell lines (not intact tissue fragments) in recipient mice lacking a full complement of 171 
immune cells31. In our hands, the selective EP4 antagonist L-161982, did not reverse the sensitivity to 172 
mechanical stimulation..  173 
 In summary, we show that induction of endometriosis in mice with an intact immune system is 174 
associated with maladaptation of the CNS, consistent with central sensitization4. We have demonstrated 175 
striking reversal of both peripheral and secondary hyperalgesia via EP2 antagonism. In conclusion, we 176 
present evidence that a murine model of endometriosis displaying local and central sensitization can be 177 
used for pre-clinical testing of therapeutics for endometriosis-associated pain.  178 
 179 
Methods  180 
 181 
Mouse model of endometriosis. Experiments were performed in accordance with the Guidelines of the 182 
Committee for Research and Ethical Issues of the International Association for the Study of Pain. 183 
Experiments were performed under licensed approval from the UK Home Office (London). C57BL/6 184 
mice (Harlan Laboratories; Derby, UK) were given access to food and water ad libitum, ambient 185 
temperature and humidity were 21°C and 50% respectively. Endometriosis was induced in the mice as 186 
previously described22. In brief, the endometrium of syngeneic donor mice underwent hormonal 187 
manipulation and induction of decidualization using an in-house protocol to model endometrial 188 
differentiation, breakdown and repair47: detailed analysis of tissue samples has shown that progesterone 189 
withdrawal (removal of P4 pellet) results in rapid induction of hypoxia, tissue breakdown and induction 190 
of angiogenic genes47, 48. Endometrial tissue (~6 hours post-progesterone withdrawal) was recovered by 191 
opening the horn and scraping with a scalpel. Approximately 40mg tissue (equivalent to one 192 
decidualized horn) was suspended in 0.2 ml PBS and injected into the peritoneal cavity of 193 
ovariectomised recipient mice that were supplemented with 500ng Estradiol Valerate (EV). This 194 
supplementation was maintained by subcutaneous injection of 500ng EV every 3 days (modification of 195 
previously published model). After allowing lesions to form over 21 days behavioral assessments were 196 
performed.   197 
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Behavioral assessments. All behavioral tests were performed starting 21 days after endometriosis 198 
induction on 2 consecutive days (day 21 and 22).  Mechanical allodynia was measured using calibrated 199 
Semmes-Weinstein von Frey filaments (Stoelting, Wood Vale, IL), according to the manufacturer’s 200 
instructions. Von Frey filaments were applied to the skin perpendicular to the plantar surface of the 201 
hindpaws or to the lower abdomen, as in 49, 50, 51. Filaments were applied to the abdomen or hind-paw 202 
ten times force in grams (g) of the filament evoking a withdrawal response in 50% of cases was recorded. 203 
Initial testing of the abdomen in naïve mice indicated lower thresholds in more caudal regions, in 204 
agreement with a previous report50. For the following spontaneous behavior tests mice were placed in 205 
observation boxes for two 5 min periods and manually observed by two independent investigators (one 206 
blinded to experimental group). Periods of spontaneous abdominally directed licking (an element of 207 
normal grooming behavior52) were recorded and an average generated. Excessive abdominally-directed 208 
licking has been reported to represent a useful biomarker of abdominal visceral pain46. Each time a 209 
mouse exhibited abdominal grooming was recorded as an event. The matrix of brain regions activated 210 
during pain includes areas impacting on affective behaviors, corresponding to the anxiety- and 211 
depression-like signs associated with chronic pain states53. Paradigms of altered affective sate in rodent 212 
pain models include reduced exploratory behavior54. Exploratory activity here was recorded in a 213 
modification of the open-field setting55, 56, with mice retained within their home box with a cardboard 214 
tunnel in the centre of the enclosure; open-field tunnel entries were manually recorded by two 215 
independent investigators (one blinded to experimental group).  216 
Experimental groups and sample collection. Four groups of mice were analysed; (i) naïve controls 217 
(no surgical procedures; n=9), (ii) OVX+E2 controls (n=9), for which, mice were ovariectomised and 218 
given E2 valerate s.c. 500 ng in sesame oil every 2 days to mirror the surgical and hormonal status on 219 
the Endo mice; (Sigma, UK), (iii) OVX+E2+PBS controls (n=6); as in group ii plus i.p injection of 220 
PBS, to mirror injection of tissue as in Endo mice (iv) endometriosis mice (Endo mice; as group iii, 221 
with ‘menstrual’ donor material in PBS injected i.p (n=18)). On day 23 mice were culled and the 222 
following samples recovered: peritoneal fluid (PF, recovered as in 57 by injecting 3 ml ice cold PBS 223 
into the peritoneal cavity followed by gentle massage and recovery (approximately 2 ml was 224 
recovered from the injected 3ml). PF was then centrifuged and frozen), peritoneal biopsy, 225 
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endometriotic lesions, L5-L6 DRGs, lumbar spinal cord, thalamus and anterior cingulate cortex. 226 
Samples were collected into RNAlater and frozen (Applied Biosystems, Warrington, UK), neutral-227 
buffered formalin prior to paraffin embedding for immunohistochemical analysis (uterus, peritoneum, 228 
and endometriosis lesions) or frozen on dry ice prior to sectioning and immunofluorescence staining 229 
(DRG) or protein extraction for Western blot analysis (spinal cord and brain). Endometriotic lesions 230 
were recognized as red, brown or white tissue deposits on the visceral or parietal peritoneum and were 231 
carefully dissected away from any surrounding fat or peritoneum. The presence of glands plus stroma 232 
in suspected lesions were confirmed by haematoxylin/eosin staining. Biopsies that did not contain 233 
both glands and stroma were not included in further analysis.  234 
Antagonists. Agents for i.p. injections were dissolved in 10% dimethylsulphoxide, 50% PEG-400, 40% 235 
ddH2O and injected in a volume of 100 μl/25g using 30 mg/kg JNJ 17203212 (TRPV1 antagonist), 10 236 
mg/kg TG6-10-1 (EP2 antagonist; Calbiochem)58, 10 mg/kg PF-0441894825 (EP2 antagonist; Abcam),10 237 
mg/kg L-161982 (EP4 antagonist; Abcam). Von Frey testing was performed at 30, 45 and 60 minutes 238 
post injection: for PF-0418948, testing was also carried out at 75 minutes). PF-04418948 (10 mg/kg in 239 
0.5% w/v methylcellulose + 0.1% V/V Tween-20 in purified water) was also administered as an oral 240 
gavage and the von Frey test performed every 15 mins starting at 30 mins.  241 
Quantitative real time PCR. RNA was extracted from control uterine biopsies recovered from naïve 242 
mice, peritoneal biopsies from naïve and endometriosis mice, endometriosis lesions and dorsal root 243 
ganglia using an RNeasy kit (QIAGEN) according to the manufacturers instructions.  RNA was 244 
quantified using a NanoDrop ND 1000. Quantitative PCR was performed as detailed in59, 60; briefly, 245 
cDNA was synthesized using SuperScript VILO enzyme (Invitrogen) with 100ng starting template. 246 
PCRs were performed using Roche Universal Probe Library (Roche Applied Science) using primer 247 
sequences detailed in Supplementary Table 2. 18S was used as a reference gene. Thermal cycling was 248 
performed on a 7900 Fast real-time PCR machine. Data was analysed with RQ manager software 249 
(Applied Biosystems) using the ∆∆Ct method; samples were normalised to a uterine control sample.  250 
Immunodetection. Single antigen immunohistochemistry was performed according to standard 251 
protocols 47, 61 with citrate antigen retrieval.  252 
Dual immunofluorescence 253 
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Dorsal root ganglia (DRGs) were embedded in OCT (CellPath) and frozen on dry ice. Sixteen μm 254 
cryostat sections were blocked for 1 hour at room temperature then incubated with primary antibodies 255 
(supplementary Table 3). Specificity of the TRPV1 antibody has been previously established62. 256 
Secondary antibodies, from Molecular Probes or Sigma-Aldrich, goat anti-chicken Alexafluor 488 257 
(1:1000), goat anti-guinea pig AlexaFluor 568 (1:1000) or goat anti-guinea-pig CF405A (1:1000) were 258 
applied for 1 hour. Sections were mounted in ProLong® Gold Antifade (Life Technologies). Confocal 259 
images were acquired at x20 magnification using a Nikon A1R microscope and ImageJ software was 260 
used to quantify co-staining. Standard controls omitting primary antibodies were immunonegative.  261 
Prostaglandin E2 (PGE2) ELISA. Approximately 2 ml of the PF was collected into tubes containing 262 
indomethacin (10µM) to prevent ex vivo PGE2 metabolism.  PGE2 levels were analyzed using DetectX® 263 
prostaglandin E2 enzyme immunoassay kit (Arbor Assays, MI, USA). 264 
Western blotting 265 
Tissue samples were collected into sealable tubes and frozen on dry ice, and then subsequently 266 
homogenized in Laemmli buffer, heated to 80°C for 5 min and centrifuged. Aliquots of lysate 267 
supernatant were analysed using the NuPage XCell SureLockTM Minicell gel electrophoresis system 268 
(Invitrogen) with approximately 12μg protein loaded per lane. Membranes were incubated overnight at 269 
4°C in 2% non-fat dried milk in 0.1 M PBS with 0.1% Tween-20, containing anti-COX-2 antibody 270 
(Supplementary Table 3)63. Membranes were washed and incubated for 50 min at room temperature 271 
with peroxidase-conjugated donkey anti-rabbit antibody (Chemicon, 1:20,000) and detected by 272 
peroxidase-linked enhanced chemiluminescence. Membranes were re-probed with mouse monoclonal 273 
anti-GAPDH (Supplementary Table 2). Films were scanned and band intensities were quantified by 274 
densitometry using ImageJ. 275 
 276 
Statistical analysis. Statistical analysis used a one-way ANOVA with a Newman Keuls or Tukey’s test, 277 
or a Kruskal Wallis with a Dunn’s multiple comparison test. A p value of less than 0.05 was considered 278 
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Fig.1│Behavior testing in control and endometriosis mice. Endometriosis mice, together 513 
withovariectomised, estradiol-treated sham recipients, with or without i.p injection of PBS, and naïve 514 
controls were scored for general behaviors indicative of discomfort that might be associated with pelvic 515 
pain. (a) Shows abdominally directed licking (average number of grooming events recorded by two 516 
observers over two 5 min periods) was significantly increased in endometriosis mice (n=5) compared to 517 
estradiol-treated (OVX+E2; n=3, OVX+E2+PBS; n=6) and naïve controls (n=7). (b) Shows that 518 
exploratory activity (average number of open-field tunnel entries recorded by two observers was 519 
significantly reduced in endometriosis mice (n=9) compared to estradiol-treated (OVX+E2; n=6, 520 
OVX+E2+PBS; n=6) and naïve controls (n=11). Mechanical withdrawal threshold, shown by von Frey 521 
filament testing, was also measured on the lower abdomen and plantar hind-paw of endometriosis mice 522 
(n=6), OVX+E2, OVX+E2+PBS (n=6) and naïve controls (n=7). For quantitative sensory testing, von 523 
Frey filaments were applied to caudal regions of the abdomen; (c) and (d) show that withdrawal 524 
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thresholds (g = grams) for both abdomen and paw testing were significantly decreased in endometriosis 525 
mice compared to the other groups. Statistical analysis was performed using a one-way ANOVA and 526 
Newman-Keuls post-hoc test (a and b) or a Kruskall-Wallis test and Dunn’s multiple comparison test. 527 
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 532 
Fig.2│Molecular changes in the nervous system of mice with endometriosis. Expression of the PGE2 533 
pathway and nociceptive ion channels is elevated in the DRGs, spinal cord and brain of mice with 534 
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endometriosis. (a-d) QPCR analysis of the prostaglandin E receptor (a) EP2, (b) COX-1 and nociceptive 535 
ion channels (c) Scn11a and (d) Trpv1 in L5-L6 DRGs from mice with endometriosis (n=9) compared 536 
to naïve (n=7) and OVX+E2 control mice (n=6). RQ: Relative quantification. Values were normalized 537 
to a single naïve DRG sample given the arbitrary value of one. (e-f) Dual label immunofluorescence 538 
was carried out to identify TRPV1 expression (red) in L5-6 DRG cells co-expressing peripherin (green). 539 
(e) Shows typical confocal images for TRPV1 and peripherin from naïve, OVX+E2-treated sham-540 
recipient and endometriosis mice (field of view, 160x 160μm). Total cells counted were 330, 320, and 541 
543, accumulated from three different naïve, OVX+E2-treated and endometriosis mice in each case. (f) 542 
Shows a bar chart that summarizes % expression of TRPV1 in peripherin-positive cells and indicates 543 
that the number of TRPV1+peripherin+ small DRG cells is significantly increased in mice with 544 
endometriosis. (g-i) Images (i) show representative examples of COX-2 (top panel; 80 kDa) and 545 
GAPDH (bottom panel; 36 kDa) expression as analyzed using Western blot in (g) spinal cord, (h) 546 
thalamus, (i) and anterior cingulate cortex of endometriosis mice, OVX+E2-treated sham-recipients and 547 
naïve controls, n=5-6 for all groups. (ii) Graphs showing COX-2: GAPDH densitometric ratio derived 548 
from quantitative densitometry of films. Both images and bar charts indicate marked elevation of COX-549 
2 expression in each region. No changes were observed in OVX+E2-treated and naïve controls. 550 
Statistical analysis was performed using a one-way ANOVA and Tukey’s post comparison test. 551 
*p<0.05, **p<0.01, ***p<0.001. 552 
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553 
Fig.3| Pre-clinical testing of potential therapeutics in a mouse model of endometriosis. Graphs 554 
depict 50% mechanical withdrawal thresholds for von Frey filaments (g=grams) applied to abdomen or 555 
hindpaw of mice with endometriosis or naïve controls, n=5 all groups. The time-point showing maximal 556 
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reversal of pain is shown for each antagonist. (a) Effects of the TRPV1 inhibitor JNJ 17203212 557 
(30mg/kg ip), 30 mins post-injection on abdominal withdrawal responses in mice with endometriosis 558 
compared to naïve mice.  (b) Shows corresponding results from hindpaw. Concurrently measured naïve 559 
values were 0.55±0.17g and 11.25± 1.44g respectively for abdomen and hindpaw. In both tests, 560 
withdrawal thresholds were significantly lower in mice with endometriosis (Endo+Vehicle) than in 561 
naïve controls or in naïve animals treated with the drug (Naïve+JNJ; p<0.01 and p<0.001).  This 562 
difference was modestly but not significantly attenuated by JNJ 17203212, which had no discernible 563 
effect on the responses of naïve animals. (c) Effects of the selective EP4 antagonist L-161982 (10mg/kg 564 
ip) 30 mins post i.p injection on abdominal and (d) hindpaw mechanical withdrawal thresholds. Naïve 565 
values were 0.39 ± 0.07g and 9.43 ± 1.43g. In both tests, thresholds were significantly lower in mice 566 
with endometriosis than in naïve animals treated with the drug (p<0.001). L-161982 had no discernible 567 
effect on hypersensitivity in mice with endometriosis or in naïve animals. (e) Effect of the EP2 antagonist 568 
TG6-10-1 (10mg/kg, ip), on abdominal and (f) hindpaw mechanical withdrawal thresholds at 45 mins 569 
post i.p injection. Naïve values were 0.31± 0.11g and 9.69 ± 1.62g. In both tests, thresholds were 570 
significantly lower in mice with endometriosis compared to naïve controls or in naïve animals treated 571 
with the drug (p<0.01 and p<0.001). This difference was significantly reversed by TG6-10-1 in 572 
abdominal tests (p<0.05). TG6-10-1 also induced a modest but not statistically significant pain reversal 573 
in paw tests. The highly selective EP2 antagonist PF-04418948 (10 mg/kg, i.p) significantly attenuated 574 
both (g) abdominal and (h) hindpaw mechanical hypersensitivity in mice with endometriosis (p<0.001) 575 
45 mins post injection. There was no discernible effect of PF-04418948 in naïve animals. Naïve values 576 
were 0.48 ± 0.05g and 8.77 ± 0.51g. Statistical analysis was performed using a one-way ANOVA and 577 
Tukey’s post comparison test. *p<0.05, **p<0.001, ***p<0.001.   578 
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 579 
Fig.4| Oral administration of the selective EP2 antagonist PF-04418948. To test the efficacy of oral 580 
administration of PF-04418948, the drug was administered at a dose of 10mg/kg by oral gavage and 581 
testing was initiated after 30 min. The graphs show the time-course of effects of PF-04418948 on 582 
mechanical withdrawal responses in mice with endometriosis (blue and pink lines) or naïve controls 583 
(purple lines). In both (a) the abdomen and (b) the hindpaw, withdrawal thresholds were significantly 584 
lower in endometriosis mice than in naïve controls (p<0.001). The pre-drug withdrawal thresholds in 585 
the naïve, drug-treated animals, were not discernibly different from those in naïve, untreated animals 586 
(0.55 ±0.06g for abdomen and 9.00 ± 0.67g for hindpaw). In each case the hypersensitivity due to 587 
endometriosis was substantially and significantly attenuated by PF-04418948 (p<0.001), n=5 all groups. 588 
Statistical analysis was performed using a Two-Way ANOVA and Dunnett’s multiple comparison test. 589 
*p<0.05, **p<0.001 and ***p<0.001 compared to naïve mice + pharmacological agent. +p<0.05, 590 
++p<0.01 and +++p<0.001 compared to pre-administration baseline.  591 
 592 
